Skip to main content

The skyline of midtown Manhattan is seen in this file photo.

Gary Hershorn/Reuters

Ivanhoé Cambridge, the real estate arm of the Caisse de dépôt et placement du Québec, is boosting its presence in the New York City market with an $850-million (U.S.) deal to buy a majority stake in a 45-storey office tower on the city's "Corporate Row."

Ivanhoé said on Tuesday it has bought a 51 per cent managing member interest in 1211 Avenue of the Americas from an affiliate of Beacon Capital Partners LLC.

The building is a Class A trophy asset, located between 47th and 48th streets, adjacent to iconic Rockefeller Center on a strip known as "Corporate Row."

Story continues below advertisement

The transaction is the latest in Ivanhoé's U.S. forays.

In April, it joined a partnership to buy a portfolio of 27 residential properties valued at about $1.5-billion.

In Manhattan alone, the company has invested more than $3-billion in the office and multiresidential sectors, including 1211 Avenue of the Americas.

"This investment exemplifies one of the priorities set out in our strategic plan: to build our office building portfolio in the United States by growing a critical mass of assets in key markets such as New York City," Ivanhoe Cambridge global investments president Bill Tresham said in a news release.

To better focus on residential units, office buildings and shopping centres, Ivanhoe Cambridge has been getting out of other areas, notably hotels.

The 1211 Avenue of the Americas deal is Ivanhoé Cambridge's third acquisition in a partnership with Callahan Capital Properties.

Among tenants in the tower are News America Inc., a subsidiary of Twenty-First Century Fox Inc.; Ropes and Gray LLP and Axis Reinsurance.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies